当前位置:
首页
>
产品中心 >
clinical_research >
absoluteantibody/Ab00188-23.0 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-23.0/ 200 µg
absoluteantibody/Ab00188-23.0 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-23.0/ 200 µg
商品编号:
Ab00188-23.0
品牌:
absoluteantibody
市场价:
¥6384.00
美元价:
3830.40
产品分类:
临床研究
公司分类:
clinical_research
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Description: Recombinant monoclonal antibody to IL-2R alpha (CD25). Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody Basiliximab.
Clone Number: Basiliximab
UniProt Accession Number of Target Protein:
Published Application(s): FC; Block; IF; IHC; WB
Published Species Reactivity: Human; Rhesus Monkey; Cynomolgus Monkey
Immunogen: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
Specificity: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit – binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) – T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
Application Notes: Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Antibody First Published in:
Kovarik et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation. 1997 Dec 27;64(12):1701-5. PMID:9422405 Note on publication: Describes the characterization of the pharmacokinetics of the therapeutic antibody.
Concentration: See vial label.
Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic
procedures for humans or animals.This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Species and Isotype: Rabbit IgG, kappaClone Number: Basiliximab
UniProt Accession Number of Target Protein:
Published Application(s): FC; Block; IF; IHC; WB
Published Species Reactivity: Human; Rhesus Monkey; Cynomolgus Monkey
Immunogen: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
Specificity: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit – binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) – T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
Application Notes: Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
Antibody First Published in:
Kovarik et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation. 1997 Dec 27;64(12):1701-5. PMID:9422405 Note on publication: Describes the characterization of the pharmacokinetics of the therapeutic antibody.
Product Form
Purification: Protein A affinity purified Supplied in: PBS only.
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°CConcentration: See vial label.
品牌介绍
Absolute antibody本公司服务于抗体测序、制造和工程服务提供给所有抗体使用者和不断增长的抗体。Absolute Antibody Ltd was founded in Oxford, UK, in August 2012, with the vision that all antibody users should be able to use recombinant antibodies, which are absolutely defined by their amino acid sequence. This view gained support in 2015 with a Comment in Nature magazine by Bradbury and Pluckthun (+110 co-signatories) – “Reproducibility: Standardize antibodies used in research“. Rather than creating entirely new antibodies (or antibody-like molecules), we are building a catalog by taking existing antibodies (often from hybridomas) then manufacturing them in a superior way and improving their usefulness by engineering.品牌货号名称规格absoluteantibody21 E11Anti-Api m 21 kitabsoluteantibodyBAB2Anti-Bet v 1 1 kitabsoluteantibodyBAB3Anti-Bet v 11 kitabsoluteantibodyBAB4Anti-Bet v 11 kitabsoluteantibodyBAB5Anti-Bet v 1 1 kitabsoluteantibodyBV16Anti-Bet v 1 1 kitabsoluteantibodyM0418Anti-Bet v 11 kitabsoluteantibody4C3Anti-Bla g 2 1 kitabsoluteantibody7C11Anti-Bla g 21 kitabsoluteantibodyD1Anti-Bos d 5 1 kitabsoluteantibody6A8Anti-Der f 11 kitabsoluteantibody10B9Anti-Der p 11 kitabsoluteantibody5H8Anti-Der p 11 kitabsoluteantibody4C1Anti-Neurotoxin AahII1 kitabsoluteantibodyH10Anti-Der p 21 kit
品牌分类
关注表位标记
Primary Antibodies
Recombinant Antibodies from Human Patients
Anti-Allergen Antibodies
多标签控制蛋白
Recombinant Isotype Controls
抗过敏原抗体
重组F4/80克隆CI:A3-1
体内研究用重组抗体
联络我们
服务热线:4000-520-616
(限工作日9:00-18:00)
QQ :1570468124
手机:18915418616